{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T08:07:27Z","timestamp":1770797247493,"version":"3.50.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Childhood cancer survivors have a high risk of chronic multi-organ disease that does not plateau over time. To date, there is a lack of sensitive diagnostic techniques that allow early detection of tissue damage before clinical symptoms occur, particularly regarding pulmonary function. Free-breathing phase-resolved functional lung (PREFUL) low-field magnetic resonance imaging (LF-MRI) may enable visualization and quantification of functional and structural lung damage without the need of specific contrast agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this single-center, cross-sectional diagnostic study, we performed LF-MRI in a cohort of\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200927 children and adolescents (age range: 5 to 17 years) after treatment for acute lymphoblastic leukemia (ALL;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200921) and Hodgkin\u2019s disease (HD;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20096) to determine the frequency of morphologic and functional lung parenchymal changes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Here, we show that despite the absence of clinical symptoms, significant time-dependent pulmonary ventilation and perfusion defects are detected. A negative correlation between the time after the end of therapy and defect-free lung tissue in the cohort of patients treated for ALL (Spearman-coefficient\u2009=\u2009\u2212 0.69,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0005) is observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results suggest an increase in pulmonary ventilation and perfusion defects preceding the increase in chronic disease that has already been reported in this patient population. Further research is needed to determine whether the functional abnormalities described in this study are an early morphological correlate of developing organ damage that may become clinically evident over time. PREFUL MRI may be an effective and highly sensitive tool for early detection of these changes in lung function, allowing longitudinal studies for risk stratification and potential future treatment adaptation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s43856-025-01365-w","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T17:00:56Z","timestamp":1769101256000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Free-breathing phase-resolved functional lung (PREFUL) low-field magnetic resonance imaging (LF-MRI) of pulmonary dysfunction after surviving childhood cancer"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9464-0262","authenticated-orcid":false,"given":"Alexander","family":"Dierl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3545-8196","authenticated-orcid":false,"given":"Maximilian","family":"Hinsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9399-2108","authenticated-orcid":false,"given":"Eva-Maria","family":"Wild","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8530-6783","authenticated-orcid":false,"given":"Nadine","family":"Bayerl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2897-5411","authenticated-orcid":false,"given":"Rafael","family":"Heiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0948-1421","authenticated-orcid":false,"given":"Armin M.","family":"Nagel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandy","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Vogel-Claussen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Voskrebenzev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5606-9822","authenticated-orcid":false,"given":"Nora","family":"Naumann-Bartsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Anderheiden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Huber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Schoeffl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Woelfle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Uder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8244-1261","authenticated-orcid":false,"given":"Adrian P.","family":"Regensburger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3535-2626","authenticated-orcid":false,"given":"Ferdinand","family":"Knieling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Karow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"1365_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2020.101733","volume":"71","author":"F Erdmann","year":"2021","unstructured":"Erdmann, F. et al. Childhood cancer: survival, treatment modalities, late effects and improvements over time. Cancer Epidemiol. 71, 101733 (2021).","journal-title":"Cancer Epidemiol."},{"key":"1365_CR2","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1182\/asheducation-2014.1.190","volume":"2014","author":"LB Silverman","year":"2014","unstructured":"Silverman, L. B. Balancing cure and long-term risks in acute lymphoblastic leukemia. Hematol. Am. Soc. Hematol. Educ. Program 2014, 190\u2013197 (2014).","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"1365_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100248","volume":"12","author":"WH Chang","year":"2022","unstructured":"Chang, W. H. et al. Late effects of cancer in children, teenagers and young adults: population-based study on the burden of 183 conditions, in-patient and critical care admissions and years of life lost. Lancet Reg. Health Eur. 12, 100248 (2022).","journal-title":"Lancet Reg. Health Eur."},{"key":"1365_CR4","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/ijc.30080","volume":"139","author":"M Schindler","year":"2016","unstructured":"Schindler, M. et al. Cause-specific long-term mortality in survivors of childhood cancer in Switzerland: a population-based study. Int. J. Cancer 139, 322\u2013333 (2016).","journal-title":"Int. J. Cancer"},{"key":"1365_CR5","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.pcl.2020.07.007","volume":"67","author":"H Visscher","year":"2020","unstructured":"Visscher, H., Otth, M., Feijen, E., Nathan, P. C. & Kuehni, C. E. Cardiovascular and pulmonary challenges after treatment of childhood cancer. Pediatr. Clin. North Am. 67, 1155\u20131170 (2020).","journal-title":"Pediatr. Clin. North Am."},{"key":"1365_CR6","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41409-021-01509-1","volume":"57","author":"M Otth","year":"2022","unstructured":"Otth, M. et al. Longitudinal lung function in childhood cancer survivors after hematopoietic stem cell transplantation. Bone Marrow Transpl. 57, 207\u2013214 (2022).","journal-title":"Bone Marrow Transpl."},{"key":"1365_CR7","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1200\/JCO.2014.59.8318","volume":"33","author":"SH Armenian","year":"2015","unstructured":"Armenian, S. H. et al. Long-term pulmonary function in survivors of childhood cancer. J. Clin. Oncol. 33, 1592\u20131600 (2015).","journal-title":"J. Clin. Oncol."},{"key":"1365_CR8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1053\/j.semnuclmed.2018.10.010","volume":"49","author":"J Mortensen","year":"2019","unstructured":"Mortensen, J. & Berg, R. M. G. Lung Scintigraphy in COPD. Semin. Nucl. Med. 49, 16\u201321 (2019).","journal-title":"Semin. Nucl. Med."},{"key":"1365_CR9","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1053\/j.semnuclmed.2017.08.001","volume":"47","author":"M Tulchinsky","year":"2017","unstructured":"Tulchinsky, M., Fotos, J. S., Wechalekar, K. & Dadparvar, S. Applications of ventilation-perfusion scintigraphy in surgical management of chronic obstructive lung disease and cancer. Semin. Nucl. Med 47, 671\u2013679 (2017).","journal-title":"Semin. Nucl. Med"},{"key":"1365_CR10","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1007\/s00247-019-04594-z","volume":"50","author":"FW Hirsch","year":"2020","unstructured":"Hirsch, F. W. et al. The current status and further prospects for lung magnetic resonance imaging in pediatric radiology. Pediatr. Radio. 50, 734\u2013749 (2020).","journal-title":"Pediatr. Radio."},{"key":"1365_CR11","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1148\/radiol.2019190452","volume":"293","author":"AE Campbell-Washburn","year":"2019","unstructured":"Campbell-Washburn, A. E. et al. Opportunities in interventional and diagnostic imaging by using high-performance low-field-strength MRI. Radiology 293, 384\u2013393 (2019).","journal-title":"Radiology"},{"key":"1365_CR12","doi-asserted-by":"publisher","first-page":"627","DOI":"10.21037\/qims.2018.08.09","volume":"8","author":"S Rashid","year":"2018","unstructured":"Rashid, S. et al. Cardiac balanced steady-state free precession MRI at 0.35 T: a comparison study with 1.5 T. Quant. Imaging Med. Surg. 8, 627\u2013636 (2018).","journal-title":"Quant. Imaging Med. Surg."},{"key":"1365_CR13","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.221250","volume":"306","author":"R Heiss","year":"2023","unstructured":"Heiss, R. et al. Pulmonary dysfunction after pediatric COVID-19. Radiology 306, e221250 (2023).","journal-title":"Radiology"},{"key":"1365_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.mri.2020.11.004","volume":"76","author":"R Heiss","year":"2021","unstructured":"Heiss, R. et al. High-performance low field MRI enables visualization of persistent pulmonary damage after COVID-19. Magn. Reson. Imaging 76, 49\u201351 (2021).","journal-title":"Magn. Reson. Imaging"},{"key":"1365_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/jmri.27027","volume":"52","author":"L Behrendt","year":"2020","unstructured":"Behrendt, L. et al. Validation of automated perfusion-weighted phase-resolved functional lung (PREFUL)-MRI in patients with pulmonary diseases. J. Magn. Reson. Imaging 52, 103\u2013114 (2020).","journal-title":"J. Magn. Reson. Imaging"},{"key":"1365_CR16","doi-asserted-by":"publisher","first-page":"e0244638","DOI":"10.1371\/journal.pone.0244638","volume":"15","author":"J Glandorf","year":"2020","unstructured":"Glandorf, J. et al. Comparison of phase-resolved functional lung (PREFUL) MRI derived perfusion and ventilation parameters at 1.5T and 3T in healthy volunteers. PLoS ONE 15, e0244638 (2020).","journal-title":"PLoS ONE"},{"key":"1365_CR17","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1002\/mrm.26893","volume":"79","author":"A Voskrebenzev","year":"2018","unstructured":"Voskrebenzev, A. et al. Feasibility of quantitative regional ventilation and perfusion mapping with phase-resolved functional lung (PREFUL) MRI in healthy volunteers and COPD, CTEPH, and CF patients. Magn. Reson. Med. 79, 2306\u20132314 (2018).","journal-title":"Magn. Reson. Med."},{"key":"1365_CR18","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1002\/jmri.27385","volume":"53","author":"GH P\u00f6hler","year":"2021","unstructured":"P\u00f6hler, G. H. et al. Repeatability of phase-resolved functional lung (PREFUL)-MRI ventilation and perfusion parameters in healthy subjects and COPD patients. J. Magn. Reson. Imaging 53, 915\u2013927 (2021).","journal-title":"J. Magn. Reson. Imaging"},{"key":"1365_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/nbm.4088","volume":"32","author":"F Klime\u0161","year":"2019","unstructured":"Klime\u0161, F. et al. Free-breathing quantification of regional ventilation derived by phase-resolved functional lung (PREFUL) MRI. NMR Biomed. 32, e4088 (2019).","journal-title":"NMR Biomed."},{"key":"1365_CR20","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1002\/jmri.26799","volume":"50","author":"T Moher Alsady","year":"2019","unstructured":"Moher Alsady, T. et al. MRI-derived regional flow-volume loop parameters detect early-stage chronic lung allograft dysfunction. J. Magn. Reson. Imaging 50, 1873\u20131882 (2019).","journal-title":"J. Magn. Reson. Imaging"},{"key":"1365_CR21","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1016\/S1470-2045(23)00012-8","volume":"24","author":"MJ Ehrhardt","year":"2023","unstructured":"Ehrhardt, M. J. et al. Systematic review and updated recommendations for cardiomyopathy surveillance for survivors of childhood, adolescent, and young adult cancer from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 24, e108\u2013e120 (2023).","journal-title":"Lancet Oncol."},{"key":"1365_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102487","volume":"69","author":"M Otth","year":"2024","unstructured":"Otth, M. et al. Recommendations for surveillance of pulmonary dysfunction among childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. EClinicalMedicine 69, 102487 (2024).","journal-title":"EClinicalMedicine"},{"key":"1365_CR23","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/mpo.2950140403","volume":"14","author":"RW Miller","year":"1986","unstructured":"Miller, R. W. et al. Pulmonary function abnormalities in long-term survivors of childhood cancer. Med. Pediatr. Oncol. 14, 202\u2013207 (1986).","journal-title":"Med. Pediatr. Oncol."},{"key":"1365_CR24","first-page":"71","volume":"7","author":"H Eigen","year":"1985","unstructured":"Eigen, H. & Wyszomierski, D. Bleomycin lung injury in children. Pathophysiology and guidelines for management. Am. J. Pediatr. Hematol. Oncol. Spring 7, 71\u201378 (1985).","journal-title":"Am. J. Pediatr. Hematol. Oncol. Spring"},{"key":"1365_CR25","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1056\/NEJM198007243030403","volume":"303","author":"PA Aronin","year":"1980","unstructured":"Aronin, P. A. et al. Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: an assessment of risk factors. N. Engl. J. Med. 303, 183\u2013188 (1980).","journal-title":"N. Engl. J. Med."},{"key":"1365_CR26","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S0022-3476(78)80443-0","volume":"92","author":"CS Alvarado","year":"1978","unstructured":"Alvarado, C. S., Boat, T. F. & Newman, A. J. Late-onset pulmonary fibrosis and chest deformity in two children treated with cyclophosphamide. J. Pediatr. 92, 443\u2013446 (1978).","journal-title":"J. Pediatr."},{"key":"1365_CR27","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1136\/jcp.25.8.668","volume":"25","author":"BW Codling","year":"1972","unstructured":"Codling, B. W. & Chakera, T. M. Pulmonary fibrosis following therapy with Melphalan for multiple myeloma. J. Clin. Pathol. 25, 668\u2013673 (1972).","journal-title":"J. Clin. Pathol."},{"key":"1365_CR28","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1517\/14740338.4.4.723","volume":"4","author":"O Lateef","year":"2005","unstructured":"Lateef, O., Shakoor, N. & Balk, R. A. Methotrexate pulmonary toxicity. Expert Opin. Drug Saf. 4, 723\u2013730 (2005).","journal-title":"Expert Opin. Drug Saf."},{"key":"1365_CR29","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1002\/1097-0142(197610)38:4<1529::AID-CNCR2820380414>3.0.CO;2-E","volume":"38","author":"PH Gutin","year":"1976","unstructured":"Gutin, P. H. et al. Methotrexate pneumonitis induced by intrathecal methotrexate therapy: a case report with pharmacokinetic data. Cancer 38, 1529\u20131534 (1976).","journal-title":"Cancer"},{"key":"1365_CR30","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1002\/1097-0142(19821215)50:12<2771::AID-CNCR2820501213>3.0.CO;2-T","volume":"50","author":"PH Konits","year":"1982","unstructured":"Konits, P. H., Aisner, J., Sutherland, J. C. & Wiernik, P. H. Possible pulmonary toxicity secondary to vinblastine. Cancer 50, 2771\u20132774 (1982).","journal-title":"Cancer"},{"key":"1365_CR31","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1136\/thoraxjnl-2011-200618","volume":"66","author":"R Mulder","year":"2011","unstructured":"Mulder, R. et al. Pulmonary function impairment measured by pulmonary function tests in long-term survivors of childhood cancer. Thorax 66, 1065\u20131071 (2011).","journal-title":"Thorax"},{"key":"1365_CR32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3892\/ol.2022.13629","volume":"25","author":"J Kruseova","year":"2023","unstructured":"Kruseova, J., Zichova, A. & Eckschlager, T. Premature aging in childhood cancer survivors. Oncol. Lett. 25, 43 (2023).","journal-title":"Oncol. Lett."},{"key":"1365_CR33","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1200\/JCO.22.02240","volume":"41","author":"AJ Esbenshade","year":"2023","unstructured":"Esbenshade, A. J. et al. Accumulation of chronic disease among survivors of childhood cancer predicts early mortality. J. Clin. Oncol. 41, 3629\u20133641 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1365_CR34","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1080\/0284186X.2017.1423177","volume":"57","author":"OH Myrdal","year":"2018","unstructured":"Myrdal, O. H. et al. Risk factors for impaired pulmonary function and cardiorespiratory fitness in very long-term adult survivors of childhood acute lymphoblastic leukemia after treatment with chemotherapy only. Acta Oncol. 57, 658\u2013664 (2018).","journal-title":"Acta Oncol."},{"key":"1365_CR35","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1186\/s12890-021-01783-1","volume":"21","author":"JP Finnerty","year":"2021","unstructured":"Finnerty, J. P., Ponnuswamy, A., Dutta, P., Abdelaziz, A. & Kamil, H. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis. BMC Pulm. Med. 21, 411 (2021).","journal-title":"BMC Pulm. Med."},{"key":"1365_CR36","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1056\/NEJMoa2503643","volume":"392","author":"TM Maher","year":"2025","unstructured":"Maher, T. M. et al. Nerandomilast in patients with progressive pulmonary fibrosis. N. Engl. J. Med. 392, 2203\u20132214 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1365_CR37","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1056\/NEJMoa2414108","volume":"392","author":"L Richeldi","year":"2025","unstructured":"Richeldi, L. et al. Nerandomilast in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 392, 2193\u20132202 (2025).","journal-title":"N. Engl. J. Med."}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01365-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01365-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01365-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T03:04:24Z","timestamp":1770779064000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01365-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1365"],"URL":"https:\/\/doi.org\/10.1038\/s43856-025-01365-w","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"assertion":[{"value":"11 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.H., M.U., and R.H. are part of the speakers\u2019 bureau of Siemens Healthineers GmbH. R.G. is an employee of Siemens Healthineers (Erlangen, Germany). J.VC. and A.V. are shareholders in BioVisioneers GmbH, a company with an interest in pulmonary MRI methods. F.K. is a member of the advisory board of iThera Medical GmbH, Munich, Germany, received travel support from iThera Medical GmbH, Germany, UCB Pharma, Germany and Sanofi Aventis, Germany. F.K. reports lecture fees from Sanofi Aventis, Germany and Siemens Healthcare GmbH, Germany. A.P.R. received travel support from iThera Medical GmbH, Germany and Sanofi Aventis, Germany. N.B. is supported by the IZKF Clinician Scientist Program and the IZKF Laboratory Rotation Program of the Medical Faculty of the Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg.All other authors declare no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"99"}}